Owens & Minor Shares Soar 36% After Firm Reports Record Q4 Earnings and Positive 2021 Outlook
Source: Streetwise Reports  (2/24/21)
Shares of Owens & Minor Inc. soared to a new 52-week high after the company reported Q4/20 and FY/20 financial results that were boosted by a 58% gain in global products revenue and increases in elective medical procedures. More >

Company's Antibiotic-Free Livestock Feed Product Shows Positive Results in Subclinical Mastitis Dairy Trial
Source: Streetwise Reports  (2/22/21)
Avivagen Inc. reported that data from a New Zealand OxC-betaTâ„¢ Livestock Dairy Trial for use against sub-clinical mastitis has been published in a top-tier international veterinary science journal. More >

Regenerative Medicine Firm Reports Positive Chronic Lower Back Pain Trial Results
Source: Streetwise Reports  (2/17/21)
New study data and next steps for Mesoblast's MPC-06-ID are presented in a Dawson James Securities report. More >

Virtual HealthCare Tech Firm Contracts with California Network of 500+ Doctors and 50 Clinics
Source: Streetwise Reports  (2/17/21)
Reliq Health Technologies reported it signed a new contract with a care management network for its iUGO Care platform to deliver customized healthcare to senior citizens in the Asian-American community throughout California. More >

Digital Therapeutics Leader DarioHealth Makes a Critical Acquisition
Source: Matt Badiali for Streetwise Reports  (2/17/21)
Independent financial analyst Matt Badiali discusses DarioHealth's latest acquisition and what it means for the company's growth. More >

Nektar Therapeutics Planning Phase 2/3 Studies with Merck and SFJ Pharma for Head and Neck Cancer
Source: Streetwise Reports  (2/17/21)
Nektar Therapeutics shares traded 14% higher after the company reported it plans to conduct a Phase 2/3 study of bempegaldesleukin in combination with Merck's KEYTRUDA® in patients with squamous cell carcinoma of the head and neck and is partnering on a second Phase 2/3 study with SFJ Pharmaceuticals that will provide $150 million to fund development. More >

PAVmed Shares Increase 28% after First US Patient Treated with CarpX Device for Carpal Tunnel Syndrome
Source: Streetwise Reports  (2/16/21)
PAVmed Inc. shares reached a new 52-week high after the company reported that the first patient in the U.S. was successfully treated with its CarpX^® Device, a minimally invasive carpal tunnel release surgical instrument. More >

Pharma Developer Contemplates Adding Lung Scarring as Key Endpoint in Phase 2b/3 COVID-19 Trial
Source: Streetwise Reports  (2/12/21)
Algernon Pharmaceuticals reported it is considering adding "lung scarring" as an additional primary endpoint to its Phase 2b/3 COVID-19 Ifenprodil study protocol. More >

ImmunoGen Shares Rise 30% After Firm Reports FY20 Earnings and 2021 Outlook
Source: Streetwise Reports  (2/12/21)
Shares of ImmunoGen Inc. reached a new 52-week high after the company announced Q4/20 and FY/20 business operating and financial results. More >

AC Immune Reports 'Positive Interim Results' from Novel Phase 1b/2a Alzheimer's Vaccine Trial
Source: Streetwise Reports  (2/11/21)
Shares of AC Immune SA traded 15% higher after the firm reported that interim results from the Phase 1b/2a Alzheimer's trial of its ACI-35.030 vaccine demonstrated generation of potent anti-phospho-Tau antibody responses in 100% of older patients with early Alzheimer's disease. More >

Pharmaceutical Developer Hires Laboratory to Conduct Preclinical Studies of Psychedelic Compound DMT
Source: Streetwise Reports  (2/10/21)
Algernon Pharmaceuticals entered into an agreement with Charles River Laboratories, "a recognized world leader for pre-clinical neurological studies," to conduct preclinical studies for psychedelic compound DMT in stroke patients. More >

Pacific Biosciences Shares Rise 22% on $900 Million Investment from Japan's SoftBank
Source: Streetwise Reports  (2/10/21)
Shares of Pacific Biosciences of California traded to a new 52-week high after the firm reported that a Softbank Group subsidiary will invest $900 million to support its growth initiatives. More >

Drug Repurposer Ventures into New Area, Use of Psychedelic in Stroke
Source: Streetwise Reports  (2/5/21)
This clinical program of Algernon Pharmaceuticals and upcoming catalysts regarding its in-progress COVID-19 and chronic cough trials are discussed in a Mackie Research Capital Corp. report. More >

Coverage Initiated on Firm Developing Gold Nanoparticle Therapy for Neurological Diseases
Source: Streetwise Reports  (2/5/21)
The reasons Clene is a compelling investment are outlined in a ROTH Capital Partners report. More >

Small-Cap Psychedelic Wellness Company Makes First Acquisition: Ketamine Infusion Centers
Source: Streetwise Reports  (2/4/21)
DELIC aims to become a leader in psychedelic health and wellness clinics. More >

Align Technology Shares Grind 12.5% Higher after Firm Posts Record Q4 Revenue of $834.5 Million
Source: Streetwise Reports  (2/4/21)
Align Technology shares set a new 52-week high after the company announced financial results that included record FY/20 total revenues of $2.5 billion. More >

Neurosciences Firm Provides Insight on Recent Alzheimer's/Amyloid Field Developments
Source: Streetwise Reports  (2/3/21)
ProMIS Neurosciences offered its perspective on the latest progress in the Alzheimer's/amyloid field. The firm stated that two recent positive events support the case for PMN310 to be considered "best in class." More >

GW Pharmaceuticals Shares Gain 46% on $7.2 Billion Acquisition by Jazz Pharmaceuticals
Source: Streetwise Reports  (2/3/21)
Shares of GW Pharmaceuticals reached a new 52-week high after the company reported it agreed to be acquired by Jazz Pharmaceuticals in a combination cash and stock deal for $220.00 per share. More >

Cassava Shares Triple After Interim Trial Data Shows Simufilam Improves Cognition and Behavior in Alzheimer's Disease
Source: Streetwise Reports  (2/2/21)
Shares of Cassava Sciences traded 207% higher after the firm provided an interim analysis from an ongoing study demonstrating that simufilam improves cognition and behavior in mild-to-moderate Alzheimer's disease patients. More >

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT, the 'Spirit Molecule'
Source: Streetwise Reports  (2/1/21)
Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that it has established a clinical research program for the treatment of stroke focused on AP-188 (DMT), a known psychedelic compound. Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021. More >

Viela Bio Shares Rise 52% on $3.05 Billion Buyout by Horizon Therapeutics
Source: Streetwise Reports  (2/1/21)
Shares of Viela Bio traded higher after it was announced that the company entered into a definitive agreement to be acquired by Horizon Therapeutics for $53.00 per share. More >

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports  (1/29/21)
Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial. More >

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports  (1/28/21)
Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19. More >

Coverage Initiated on Biotech 'Improving Drugs Via Prodrug'
Source: Streetwise Reports  (1/27/21)
KemPharm's key near-term catalyst, lead value driver and other pipeline drug candidates are discussed in a ROTH Capital Partners report. More >

Life Sciences Co. Receives Large Livestock Feed Order from New Client in Mexico
Source: Streetwise Reports  (1/27/21)
Avivagen Inc. reported it has secured a six tonne order for OxC-betaâ„¢ Livestock from a new customer in Queretaro City, Mexico. More >